List of Excipients in API taletrectinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing taletrectinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Nuvation Bio Inc | IBTROZI | taletrectinib | 84651-200 | ALCOHOL | 2030-06-11 |
| Nuvation Bio Inc | IBTROZI | taletrectinib | 84651-200 | AMMONIA | 2030-06-11 |
| Nuvation Bio Inc | IBTROZI | taletrectinib | 84651-200 | BUTYL ALCOHOL | 2030-06-11 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for taletrectinib
Excipient focus: ALCOHOL
taletrectinib drug variants containing ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Nuvation Bio Inc | taletrectinib | 84651-200 |
| >Company | >Ingredient | >NDC |
taletrectinib drug variants not containing ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: AMMONIA
taletrectinib drug variants containing AMMONIA
| Company | Ingredient | NDC |
|---|---|---|
| Nuvation Bio Inc | taletrectinib | 84651-200 |
| >Company | >Ingredient | >NDC |
taletrectinib drug variants not containing AMMONIA
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: BUTYL ALCOHOL
taletrectinib drug variants containing BUTYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Nuvation Bio Inc | taletrectinib | 84651-200 |
| >Company | >Ingredient | >NDC |
taletrectinib drug variants not containing BUTYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C BLUE NO. 1 ALUMINUM LAKE
taletrectinib drug variants containing FD&C BLUE NO. 1 ALUMINUM LAKE
| Company | Ingredient | NDC |
|---|---|---|
| Nuvation Bio Inc | taletrectinib | 84651-200 |
| >Company | >Ingredient | >NDC |
taletrectinib drug variants not containing FD&C BLUE NO. 1 ALUMINUM LAKE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
taletrectinib drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Nuvation Bio Inc | taletrectinib | 84651-200 |
| >Company | >Ingredient | >NDC |
taletrectinib drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: ISOPROPYL ALCOHOL
taletrectinib drug variants containing ISOPROPYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Nuvation Bio Inc | taletrectinib | 84651-200 |
| >Company | >Ingredient | >NDC |
taletrectinib drug variants not containing ISOPROPYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
taletrectinib drug variants containing LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Nuvation Bio Inc | taletrectinib | 84651-200 |
| >Company | >Ingredient | >NDC |
taletrectinib drug variants not containing LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
taletrectinib drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| Nuvation Bio Inc | taletrectinib | 84651-200 |
| >Company | >Ingredient | >NDC |
taletrectinib drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL
taletrectinib drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Nuvation Bio Inc | taletrectinib | 84651-200 |
| >Company | >Ingredient | >NDC |
taletrectinib drug variants not containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SHELLAC
taletrectinib drug variants containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| Nuvation Bio Inc | taletrectinib | 84651-200 |
| >Company | >Ingredient | >NDC |
taletrectinib drug variants not containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
taletrectinib drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Nuvation Bio Inc | taletrectinib | 84651-200 |
| >Company | >Ingredient | >NDC |
taletrectinib drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STEARYL FUMARATE
taletrectinib drug variants containing SODIUM STEARYL FUMARATE
| Company | Ingredient | NDC |
|---|---|---|
| Nuvation Bio Inc | taletrectinib | 84651-200 |
| >Company | >Ingredient | >NDC |
taletrectinib drug variants not containing SODIUM STEARYL FUMARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: STARCH, CORN
taletrectinib drug variants containing STARCH, CORN
| Company | Ingredient | NDC |
|---|---|---|
| Nuvation Bio Inc | taletrectinib | 84651-200 |
| >Company | >Ingredient | >NDC |
taletrectinib drug variants not containing STARCH, CORN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
taletrectinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Nuvation Bio Inc | taletrectinib | 84651-200 |
| >Company | >Ingredient | >NDC |
taletrectinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch